FREE patent keyword monitoring and additional FREE benefits. http://images1.freshpatents.com/images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents

Browse: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 3 |

Novartis Corporate Intellectual Property patents

The following is a sampling of recent Novartis Corporate Intellectual Property patent applications (USPTO Patent Application #, Patent Title) sorted by month.

February 2011 - Novartis Corporate Intellectual Property patents

20110045062 - Formulation
20110045511 - Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said method
20110046150 - Use of n--4-(3-pyridyl)-2-pyridine-amine for the treatment of pulmonary hypertension
20110046190 - Combinations comprising a selective cyclooxygenase-2 inhibitor
20110046193 - Deferacirox dispersible tablets
20110046397 - New processes
20110037185 - Continuous process for making pharmaceutical compositions
20110038897 - Oral controlled release formulations
20110039818 - Dosage regimen of an s1p receptor agonist
20110039850 - Leukemia treatment
20110033453 - Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
20110033458 - Combinations comprising epothilones and pharmaceutical uses thereof
20110033533 - Galenical formulations of organic compounds
20110034503 - Rapamycin and its derivatives for the treatment of liver-associated fibrosing disorders
20110034509 - Beta-2-adrenoreceptor agonists
20110034531 - Use of hdac inhibitors for the treatment of melanoma
20110027284 - Nogo-a binding molecules and pharmaceutical use thereof
20110028422 - Combination of nilotinib and a nitrogen mustard analogue for the treatment of chronic lymphocytic leukemia
20110028516 - Stabilized and preserved ketoifen ophthalmic compositions
20110028526 - Valsartan solid oral dosage forms and methods of making such formulations

January 2011 - Novartis Corporate Intellectual Property patents

20110020338 - 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes
20110020368 - Treating cancer by down-regulating frizzled-4 and/or frizzled-1
20110021502 - Use of cholinesterase inhibitors for treating vascular depression
20110021536 - Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts
20110015425 - Process
20110005518 - Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
20110008334 - Nogo-a binding with enhanced affinity and pharmaceutical use thereof
20110009340 - Combination of an iron chelator and an immunosuppressant and use thereof
20110009383 - Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias
20110003002 - Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers

December 2010 - Novartis Corporate Intellectual Property patents

20100326877 - Packaging pouch
20100331264 - Preserving secondary peptide structure
20100331387 - Lyophilized pharmaceutical compositions
20100323952 - Nucleoside analogs in combination therapy of herpes simplex infections
20100316713 - Pharmaceutical composition
20100317627 - Treatment of hcv disorders
20100311802 - Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
20100311805 - Combination of histone deacetylase inhibitors and radiation
20100303906 - Solid dosage forms of valsartan and amlodipine and method of making same
20100303919 - Pharmaceutical compositions comprising fluvastatin
20100305150 - Tuberous sclerosis treatment

November 2010 - Novartis Corporate Intellectual Property patents

20100298338 - Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit
20100298353 - Famciclovir for the treatment of recurrent herpes labialis using a one-day treatment
20100287884 - Powder conditioning of unit dose drug packages
20100291216 - Pharmaceutical compositions
20100291217 - Pharmaceutical compositions
20100292291 - Formulations of deacetylase inhibitors
20100282247 - Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin
20100286031 - Antibiotic formulations, unit doses, kits and methods
20100286409 - Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
20100278824 - Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer
20100278881 - Use of calcitonin in osteoarthritis
20100280003 - Combinations of jak inhibitors
20100280035 - Solid pharmaceutical composition comprising 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine and a ph modifier
20100280257 - Process for the synthesis of organic compounds

October 2010 - Novartis Corporate Intellectual Property patents

20100272717 - Combinations of therapeutic agents for treating cancer
20100272809 - Microparticles comprising somatostatin analogues
20100272823 - Pulmonary delivery particles comprising water insoluble or crystalline active agents
20100273719 - Use of somatostatin analogs in meningioma
20100266608 - Il-17 antagonistic antibodies
20100266696 - Organic compounds
20100266704 - Octreotide depot formulation with constantly high exposure levels
20100267675 - Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
20100267682 - Corticosteroids to treat epothilone or epothilone derivative induced diarrhea
20100267786 - Dual acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and ne utral endopeptidase (ep) inhibitor
20100267787 - Pharmaceutical compositions
20100267789 - Tablet formulations comprising valsartan
20100267965 - 3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors
20100261726 - Treatment of aml
20100254976 - Use of protease nexin 1 inhibitors to reduce metastasis
20100255485 - Biomarkers for the onset of neurodegenerative diseases
20100256080 - Organic compounds

September 2010 - Novartis Corporate Intellectual Property patents

20100247608 - Pharmaceutical compositions comprising hgh for oral delivery
20100247645 - Pharmaceutical combination of aliskiren and valsartan
20100247658 - Organic compounds
20100249136 - Organic compounds
20100249204 - Calcium salts of indole derived statins
20100249429 - Process for the manufacture of valsartan
20100239524 - Microparticles prepared using an ionic liquid
20100240680 - Purine derivatives as a2a agonists
20100240744 - Methods for the treatment of dementia based on apo e genotype
20100233253 - Extended release gastro-retentive oral drug delivery system for valsartan
20100233716 - Transplant rejection markers
20100234408 - Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis
20100234467 - Methods for improving bioavailability of a renin inhibitor
20100222334 - Pharmaceutical formulation of valsartan
20100222360 - Treatment of malignant peripheral nerve sheath tumors
20100222362 - N-oxides of n-phenyl-2-pyramidine-amine derivatives

August 2010 - Novartis Corporate Intellectual Property patents

20100209418 - Solid forms of a raf kinase inhibitor
20100209480 - Galenical formulations of organic compounds
20100210526 - Oral administration of a calcitonin
20100210650 - Isoxazole compound for the treatment of cancer
20100210673 - Pyrimidylaminobenzamide derivatives for systemic mastocytosis
20100210717 - Pharmaceutical compositions comprising mycophenolic acid or mycophenolate salt
20100203133 - High drug load tablet
20100204190 - New combinations
20100196365 - Use of imidazoquinolines for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
20100196467 - Therapeutic combination of amlodipine and benazepril/benazeprilat
20100196957 - Cloning and characterization of 5' flanking regions of a human aggrecanase-1 gene
20100197629 - Oral pharmaceutical solutions containing telbivudine
20100197804 - Pharmaceutical compositions comprising terbinafine

July 2010 - Novartis Corporate Intellectual Property patents

20100190800 - Combinaton of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases
20100184820 - Combinations comprising staurosporines
20100184743 - Use of cholinesterase inhibitors for treating vascular depression
20100184779 - Method for optimizing the treatment of chronic myeloid leukemia with abl tyrosine kinase inhibitors
20100184798 - Methods to predict cholesterol elevations during immunosuppressant therapy
20100184991 - Preparation of terazole derivatives
20100184998 - Organic compounds
20100178336 - Stabilized amorphous forms of imatinib mesylate
20100178344 - Extended-release composition comprising a somatostatin derivative in microparticles
20100179175 - Use of pkc inhibitors in ocular diseases
20100179179 - Inhibitors of the mutant form of kit
20100179182 - Pharmaceutical formulation
20100179208 - Use of hdac inhibitors for the treatment of bone destruction
20100172869 - Method for treating multiple sclerosis
20100173934 - Combinations of therapeutic agents for treating cancer
20100163021 - System for delivering nebulized cyclosporine and methods of treatment
20100166671 - Organic compounds
20100166750 - Indications for anti-il-1 beta therapy
20100166758 - Novel antibody molecules and nucleic acids
20100166865 - Nanoparticle compositions
20100167302 - Method for predicting the response of a subject suffering from a viral infection of the liver to an antiviral therapy
20100168060 - Salts of benzimidazolyl pyridyl ethers and formulations thereof
20100168078 - S1p receptor modulators for treating multiple sclerosis
20100168132 - Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists
20100168153 - Salts and crystall forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile
20100168229 - Process for the preparation of optically active compounds using transfer hydrogenation

June 2010 - Novartis Corporate Intellectual Property patents

20100160257 - Use of hdac inhibitors for the treatment of myeloma
20100160259 - Dosage regimen for a s1p receptor agonist
20100160381 - Raf inhibitors for the treatment of thyroid cancer
20100160393 - Crystal form of epothilone b and use in pharmaceutical compositions
20100160437 - Topical composition comprising a cyclofructan, a carrier and a drug
20100151033 - Octreotide depot formulation with constantly high exposure levels
20100152101 - Triazol compounds for treating biofilm formation
20100152299 - Process for making compositions with poorly compressible therapeutic compounds
20100152458 - Coupling reactions useful in the preparation of (1h-tetrazol-5-yl) biphenyl derivatives
20100143493 - Ophthalmic solutions
20100143956 - Predictive renal safety biomarkers and biomarker signatures to monitor kidney function
20100144750 - Use of n-phenyl-2-pyrimidineamine derivatives against mast cell-based diseases like allergic disorders
20100144811 - Combination
20100137398 - Use of hdac inhibitors for the treatment of gastrointestinal cancers

May 2010 - Novartis Corporate Intellectual Property patents

20100126502 - Self-sealing t-piece and valved t-piece
20100130408 - Use of modified cyclosporins
20100130616 - Salt of aliskiren with orotic acid
20100130749 - Methods
20100119540 - Vaccination regimen for b-cell vaccines
20100120746 - Use of r-10-hydroxy-10,11-dihydro-carbamazepine in neuropathic pain
20100120773 - Method of treating disorders mediated by the fibroblast growth factor receptor
20100120877 - Additional therapeutic use
20100120921 - Renin inhibitors for treatment of hypertension in patients with high sodium diet
20100108058 - Powder dispersion apparatus, method of making and using the apparatus, and components that can be used on the apparatus and other devices
20100113501 - Ophthalmic composition comprising ascomycin
20100113607 - Pharmaceutical compositions
20100113801 - Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid

April 2010 - Novartis Corporate Intellectual Property patents

20100105696 - Imidazoquinolines as dual lipid kinase and mtor inhibitors
20100098662 - Treatment of liver diseases in which iron plays a role in pathogenesis
20100093603 - Use of organic compounds
20100093672 - Use of s1p receptor modulator
20100093732 - Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms
20100093739 - Method for decreasing capillary permeability in the retina
20100093749 - Compounds
20100086518 - Treatment of melanoma
20100087432 - Pyrrole derivatives having crth2 receptor antagonist activity
20100087463 - Pharmaceutical compositions comprising nilotinib or its salt
20100087545 - Purification process

March 2010 - Novartis Corporate Intellectual Property patents

20100075997 - Use of pkc inhibitors in transplantation
20100076067 - Biodegradable block copolymeric compositions for drug delivery
20100076084 - Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
20100068265 - Gelatin capsules comprising an acid
20100068288 - Mixtures or organic compounds for the treatment of airway diseases
20100068298 - Nutritional supplement composition for treatment of ocular diseases
20100069296 - Use of somatostatin analogs in cluster headache
20100069318 - Combination of an hdac inhibitor and an antimetabolite
20100069458 - Combination of lbh589 with other therapeutic agents for treating cancer
20100063029 - Use of s-10-hydroxy-10,11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders
20100055049 - Insulin derivative formulations for pulmonary delivery
20100055709 - Tubulin mutation diagnostic
20100056426 - Use of iron chelator for the treatment of myocardial infarction
20100056460 - Combination of organic compounds
20100056467 - Combination of iap inhibitors and flt3 inhibitors
20100056476 - Pharmaceutical compositions comprising peranhydrocyclodextrin
20100056481 - Crystalline forms of zoledronic acid
20100056558 - 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase inhibitors
20100056590 - Polymorphic forms of deferasirox (icl670a)

February 2010 - Novartis Corporate Intellectual Property patents

20100047306 - Pharmaceutical compositions comprising bisphosponates
20100048654 - Use of valsartan or its metabolite to in hibit platelet aggregation
20100048716 - Crystalline forms of aliskiren hemifumarate
20100038816 - Method of making solid dispersions of highly crystalline therapeutic compounds
20100040598 - Kit of parts comprising an acid labile and an acid resistant pharmaceutically active ingredient
20100040677 - Formulations for benzimidazolyl pyridyl ethers
20100040678 - Organic compounds
20100041641 - Uses of metabotropic glutamate receptors
20100041666 - Use of n-phenyl-2-pyrimidineamine derivativea against mast cell-based diseases like allergic disorders
20100041884 - Crystal modifications-3-(1h-indol-3-yl)-4- [4-methyl-piperazin-1-yl)-quinazolin-4-yl] -pyrrole-2, 5-d ione
20100041887 - Quinuclidine derivatives binding to mucarinic m3 receptors
20100041918 - Cyclopentene diol monoacetate derivatives
20100034890 - Combinations of formoterol and fluticasone propionate for asthma
20100034910 - Spray drying process control of drying kinetics
20100035949 - Microemulsion dosage forms of valsartan and methods of making the same
20100028338 - Combinations of therapeutic agents for treating cancer
20100028459 - Nutritional supplement composition for treatment of ocular diseases
20100029550 - Organic compounds
20100029647 - 3,4,(5)-substituted tetrahydrophyridines
20100029705 - Beta-2-adrenoreceptor agonists
20100029775 - Renin inhibitors for the prevention and treatment of hypertension in obese patients

January 2010 - Novartis Corporate Intellectual Property patents

20100021539 - Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
20100021920 - Mutated abl kinase domains
20100021921 - Mutated abl kinase domains
20100022627 - Predictive biomarkers for chronic allograft nephropathy
20100022565 - Pharmaceutical compositions
20100011714 - Package for medicament
20100009392 - Use of melanoma inhibitory activity (mia) protein as an early indicator for therapeutic response in melanoma
20100010039 - Polymorphic crystal form of a indan-2-ylamino-hydroxyethyl-quinolinone maleate derivative as beta-adrenoceptor agonist
20100003212 - Polymers with antimicrobial activity containing quaternary ammonium groups
20100003318 - Process for making multiparticulates using a roller compactor
20100003321 - Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same
20100004205 - Pharmaceutical compositions
20100004303 - Treatment of endocrine dysfunction using iron chelators

December 2009 - Novartis Corporate Intellectual Property patents

20090324542 - Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders
20090325912 - Quinolinone derivatives and their pharmaceutical compositions
20090325948 - Inhibitors of undecaprenyl pyrophosphate synthase
20090325967 - Adenosine derivatives as a2a receptor agonists
20090326066 - Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of nep inhibitors
20090326239 - Fermentative preparation process for and crystal forms of cytostatics
20090327175 - Pharmacokinetic modeling of mycophenolic acid
20090314639 - Means and devices for electro-filtration of molecules
20090317489 - Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
20090317827 - Receptor in dendritic cells
20090318390 - Combinations comprising epothilones and pharmaceutical uses thereof
20090318445 - Pdf inhibitors
20090308384 - Apparatus and methods for delivery of medicament to a respiratory system
20090311216 - Recombinant interferon-beta with enhanced biological activity
20090312290 - Combination of a nitrogen mustard analogue and imatinib for treatment of chronic lymphocytic leukemia
20090312304 - Organic compounds
20090312311 - Combination of organic compounds
20090312441 - Organic compounds
20090304705 - Biomarkers for chronic transplant dysfunction
20090305995 - Agonists and antagonists of the somatostatin receptor
20090306138 - Pyrrolidine derivatives acting as ccr3-receptor antagonists
20090306160 - Methods for improving drug disposition
20090306405 - Process for making n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide and starting materials therefor
20090297494 - Diagnostic and treatment of a mental disorder
20090298743 - Hydrophobic compositions containing reconstitution enhancer
20090298791 - Combinations comprising epothilones and antimetabolites
20090299064 - Methods and intermediates for the preparation of optionally radio-labeled imatinib
20090299065 - Process for the manufacture of organic compounds



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Novartis Corporate Intellectual Property in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Novartis Corporate Intellectual Property with additional patents listed. Browse our Agent directory for other possible listings.